Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Otsuka and Avanir decide to continue development of AVP-786 for agitation in Alzheimer's dementia

Nov. 12, 2019

Medshine Discovery identifies new LRRK2 inhibitors

Nov. 12, 2019

Dopamine D1 receptor positive allosteric modulators discovered at Lilly

Nov. 12, 2019

Roche announces discontinuation of RG-6206 development in DMD

Nov. 11, 2019

SUNFISH study of risdiplam in type 2 and 3 SMA meets primary endpoint

Nov. 11, 2019

New DREADD tools for noninvasive manipulation and visualization of neuronal circuits in animals

Nov. 11, 2019

Novel AVV-based vector therapy for the treatment of AD

Nov. 11, 2019

Roche and Genentech identify new RIP-1 inhibitors

Nov. 11, 2019

Targeting acquired immunity improves brain injury recovery

Nov. 8, 2019

Supernus Pharmaceuticals provides data from phase III P301 study of SPN-810

Nov. 8, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...